180 related articles for article (PubMed ID: 18026833)
1. Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas.
Bates GJ; Fox SB; Han C; Launchbury R; Leek RD; Harris AL; Banham AH
Breast Cancer Res Treat; 2008 Oct; 111(3):453-9. PubMed ID: 18026833
[TBL] [Abstract][Full Text] [Related]
2. FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer.
Shigekawa T; Ijichi N; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
Horm Cancer; 2011 Oct; 2(5):286-97. PubMed ID: 21901488
[TBL] [Abstract][Full Text] [Related]
3. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Rayoo M; Yan M; Takano EA; Bates GJ; Brown PJ; Banham AH; Fox SB
J Clin Pathol; 2009 Oct; 62(10):896-902. PubMed ID: 19622517
[TBL] [Abstract][Full Text] [Related]
4. The expression and correlation between the transcription factor FOXP1 and estrogen receptors in epithelial ovarian cancer.
Hu Z; Zhu L; Tan M; Cai M; Deng L; Yu G; Liu D; Liu J; Lin B
Biochimie; 2015 Feb; 109():42-8. PubMed ID: 25500588
[TBL] [Abstract][Full Text] [Related]
5. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
7. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas.
Fox SB; Brown P; Han C; Ashe S; Leek RD; Harris AL; Banham AH
Clin Cancer Res; 2004 May; 10(10):3521-7. PubMed ID: 15161711
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
9. FOXP1 and estrogen signaling in breast cancer.
Ijichi N; Ikeda K; Horie-Inoue K; Inoue S
Vitam Horm; 2013; 93():203-12. PubMed ID: 23810008
[TBL] [Abstract][Full Text] [Related]
10. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
11. The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness.
Sisci D; Maris P; Cesario MG; Anselmo W; Coroniti R; Trombino GE; Romeo F; Ferraro A; Lanzino M; Aquila S; Maggiolini M; Mauro L; Morelli C; Andò S
Cell Cycle; 2013 Nov; 12(21):3405-20. PubMed ID: 24047697
[TBL] [Abstract][Full Text] [Related]
12. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
[TBL] [Abstract][Full Text] [Related]
13. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
Reese JM; Suman VJ; Subramaniam M; Wu X; Negron V; Gingery A; Pitel KS; Shah SS; Cunliffe HE; McCullough AE; Pockaj BA; Couch FJ; Olson JE; Reynolds C; Lingle WL; Spelsberg TC; Goetz MP; Ingle JN; Hawse JR
BMC Cancer; 2014 Oct; 14():749. PubMed ID: 25288324
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
Zekas E; Prossnitz ER
BMC Cancer; 2015 Oct; 15():702. PubMed ID: 26470790
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptors in breast carcinogenesis and endocrine therapy.
Huang B; Warner M; Gustafsson JÅ
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():240-4. PubMed ID: 25433206
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
Iwase H; Zhang Z; Omoto Y; Sugiura H; Yamashita H; Toyama T; Iwata H; Kobayashi S
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S34-8. PubMed ID: 12819932
[TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers.
Litwiniuk MM; Roznowski K; Filas V; Godlewski DD; Stawicka M; Kaleta R; Breborowicz J
BMC Cancer; 2008 Apr; 8():100. PubMed ID: 18405391
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer.
Huang B; Omoto Y; Iwase H; Yamashita H; Toyama T; Coombes RC; Filipovic A; Warner M; Gustafsson JÅ
Proc Natl Acad Sci U S A; 2014 Feb; 111(5):1933-8. PubMed ID: 24449868
[TBL] [Abstract][Full Text] [Related]
20. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers.
Yan M; Rayoo M; Takano EA; ; Fox SB
Breast Cancer Res Treat; 2011 Apr; 126(2):395-405. PubMed ID: 20490651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
